{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:27:54Z","timestamp":1790735274300,"version":"4.1.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>Background and Aims<\/jats:title>\n            <jats:p>Thirty percent of patients with cirrhosis are obese and the prevalence of obesity increases after transplant to &gt;40% post\u2010transplant. There are currently four weight loss medications approved by the FDA for treatment of obesity (orlistat, phentermine\u2010topiramate, naltrexone\u2010bupropion, and liraglutide). The aim of this review was to investigate the data on the use of these weight loss medications and alternative medicines in patients with cirrhosis and in liver transplant recipients (LTRs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results<\/jats:title>\n            <jats:p>While there is paucity of data for these medications in patients with cirrhosis and LTRs, Liraglutide appears to be generally safe in view of its pharmacokinetic properties. Phentermine\u2010topiramate seems to have the highest weight loss potential but special consideration should be given to neuropsychiatric disorders, cardiovascular comorbidities, and drug interactions. There are emerging data on use of alternative medicines for weight loss but more data are needed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The use of weight loss medications is feasible in this patient population but the decision of which medication to prescribe should be individualized based on the degree of renal and hepatic impairment, other co\u2010morbidities, and concomitant medications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.31595","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T22:31:16Z","timestamp":1602541876000},"page":"2051-2062","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential"],"prefix":"10.1097","volume":"73","author":[{"given":"Sara A.","family":"Brown","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition,Vanderbilt University,Nashville,TN,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6402-5333","authenticated-orcid":false,"given":"Manhal","family":"Izzy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition,Vanderbilt University,Nashville,TN,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kymberly D.","family":"Watt","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,The Mayo Clinic,Rochester,MN,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"hep31595-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.24418","article-title":"Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis","volume":"54","year":"2011","journal-title":"Hepatology"},{"key":"hep31595-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/ajt.15276","article-title":"OPTN\/SRTR 2017 annual data report: liver","volume":"19","year":"2019","journal-title":"Am J Transplant"},{"key":"hep31595-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/lt.24137","article-title":"Cardiovascular disease after liver transplantation: when, what, and who is at risk","volume":"21","year":"2015","journal-title":"Liver Transplant"},{"key":"hep31595-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","year":"2019","journal-title":"Metabolism"},{"key":"hep31595-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"hep31595-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/lt.24602","article-title":"Roadmap for improving patient and graft survival in the next 10 years","volume":"22","year":"2016","journal-title":"Liver Transplant"},{"key":"hep31595-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL Clinical Practice Guidelines on nutrition in chronic liver disease","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"hep31595-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep31595-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa1700459","article-title":"Weight and metabolic outcomes 12 years after gastric bypass","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"hep31595-bib-0011-20250824","first-page":"102","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Obesity Society","volume":"129","year":"2014","journal-title":"Circulation"},{"key":"hep31595-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4158\/EP161356.ESGL","article-title":"Guidelines American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","year":"2016","journal-title":"Endocr Pract"},{"key":"hep31595-bib-0013-20250824","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"hep31595-bib-0015-20250824","first-page":"817","article-title":"Obesity management: update on orlistat","volume":"3","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"hep31595-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double\u2010blind randomized placebo\u2010controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31595-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/TCRM.S124621","article-title":"Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients","volume":"13","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"hep31595-bib-0018-20250824","first-page":"90","article-title":"Efficacy of orlistat in non\u2010alcoholic fatty liver disease: a systematic review and meta\u2010analysis","volume":"9","year":"2018","journal-title":"Biomed Reports"},{"key":"hep31595-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1432-2277.2006.00379.x","article-title":"Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial","volume":"19","year":"2006","journal-title":"Transpl Int"},{"key":"hep31595-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJM200004133421518","article-title":"Reduction in blood cyclosporine concentration by orlistat","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"hep31595-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/lt.23646","article-title":"High prevalence of vitamin a and d deficiency in patients evaluated for liver transplantation","volume":"19","year":"2013","journal-title":"Liver Transpl"},{"key":"hep31595-bib-0024-20250824","article-title":"Orlistat associated subacute hepatic failure","volume":"34","year":"2001","journal-title":"J Hepatol"},{"key":"hep31595-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/hep.30658","article-title":"Incorporating weight loss medications into hepatology practice for nonalcoholic steatohepatitis","volume":"70","year":"2019","journal-title":"Hepatology"},{"key":"hep31595-bib-0026-20250824","first-page":"330","article-title":"Controlled\u2010release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","year":"2011","journal-title":"Obesity"},{"key":"hep31595-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low\u2010dose, controlled\u2010release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo\u2010controlled, phase 3 trial","volume":"377","year":"2011","journal-title":"Lancet"},{"key":"hep31595-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.4254\/wjh.v7.i28.2819","article-title":"Treating morbid obesity in cirrhosis: a quest of holy grail","volume":"7","year":"2015","journal-title":"World J Hepatol"},{"key":"hep31595-bib-0029-20250824","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity\u2010related risk factors (COR\u2010II)","volume":"21","year":"2013","journal-title":"Obesity"},{"key":"hep31595-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/2040622315620180","article-title":"The GLP\u20101 agonist, liraglutide, as a pharmacotherapy for obesity","volume":"7","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"key":"hep31595-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep31595-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non\u2010alcoholic steatohepatitis (LEAN): a multicentre, double\u2010blind, randomised, placebo\u2010controlled phase 2 study","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"hep31595-bib-0033-20250824","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta\u2010analysis of the LEAD program","volume":"37","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"hep31595-bib-0034-20250824","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cen.12369","article-title":"Glucagon\u2010like peptide\u20101 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease","volume":"81","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"hep31595-bib-0035-20250824","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03762.x","article-title":"Influence of hepatic impairment on pharmacokinetics of the human GLP\u20101 analogue, liraglutide","volume":"70","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"hep31595-bib-0036-20250824","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2337\/dc13-1066","article-title":"Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"hep31595-bib-0037-20250824","article-title":"The Use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients","volume":"6","year":"2020","journal-title":"Transplant Direct"},{"key":"hep31595-bib-0038-20250824","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: post hoc analysis from the leader trial","volume":"138","year":"2018","journal-title":"Circulation"},{"key":"hep31595-bib-0039-20250824","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/lt.21021","article-title":"Acute liver failure induced by green tea extracts: case report and review of the literature","volume":"12","year":"2006","journal-title":"Liver Transplant"},{"key":"hep31595-bib-0040-20250824","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3945\/ajcn.111.020321","article-title":"Effects of 15\u2010d repeated consumption of Hoodia gordonii purified extract on safety, ad libitum energy intake, and body weight in healthy, overweight women: a randomized controlled trial 1\u20103","volume":"94","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"hep31595-bib-0041-20250824","first-page":"1","article-title":"Green cardamom increases Sirtuin\u20101 and reduces inflammation in overweight or obese patients with non\u2010alcoholic fatty liver disease: a double\u2010blind randomized placebo\u2010controlled clinical trial","volume":"15","year":"2018","journal-title":"Nutr Metab"},{"key":"hep31595-bib-0042-20250824","first-page":"118","article-title":"Dietary cardamom inhibits the formation of azoxymethane\u2010induced aberrant crypt foci in mice and reduces COX\u20102 and iNOS expression in the colon","volume":"6","year":"2005","journal-title":"Asian Pacific J Cancer Prev"},{"key":"hep31595-bib-0043-20250824","article-title":"Role of curcumin in disease prevention and treatment","volume":"7","year":"2018","journal-title":"Adv Biomed Res"},{"key":"hep31595-bib-0044-20250824","first-page":"1","article-title":"The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"10","year":"2019","journal-title":"Front Pharmacol"},{"key":"hep31595-bib-0045-20250824","article-title":"Curcumin and inflammation in non\u2010alcoholic fatty liver disease: a randomized, placebo controlled clinical trial","volume":"19","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"hep31595-bib-0046-20250824","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7762\/cnr.2019.8.3.196","article-title":"Does turmeric\/curcumin supplementation change anthropometric indices in patients with non\u2010alcoholic fatty liver disease? A systematic review and meta\u2010analysis of randomized controlled trials","volume":"8","year":"2019","journal-title":"Clin Nutr Res"},{"key":"hep31595-bib-0047-20250824","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12072-018-9910-x","article-title":"The effects of curcumin on the metabolic parameters of non\u2010alcoholic fatty liver disease: a meta\u2010analysis of randomized controlled trials","volume":"13","year":"2019","journal-title":"Hepatol Int"},{"key":"hep31595-bib-0048-20250824","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.transproceed.2012.01.081","article-title":"The protective effect of curcumin on ischemia\u2010reperfusion\u2010induced liver injury","volume":"44","year":"2012","journal-title":"Transplant Proc"},{"key":"hep31595-bib-0049-20250824","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.imr.2018.07.004","article-title":"Efficacy of curcumin\/turmeric on liver enzymes in patients with non\u2010alcoholic fatty liver disease: a systematic review of randomized controlled trials","volume":"8","year":"2019","journal-title":"Integr Med Res"},{"key":"hep31595-bib-0050-20250824","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2133\/dmpk.DMPK-11-RG-105","article-title":"Food\u2010drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats","volume":"27","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"hep31595-bib-0051-20250824","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1055\/s-0043-100019","article-title":"Efficacy and safety of phytosomal curcumin in non\u2010alcoholic fatty liver disease: a randomized controlled trial","volume":"67","year":"2017","journal-title":"Drug Res"},{"key":"hep31595-bib-0052-20250824","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.17554\/j.issn.2224-3992.2016.05.662","article-title":"Evaluation of L\u2010carnitine efficacy in the treatment of non\u2010 alcoholic fatty liver disease among diabetic patients: a randomized double blind pilot study","volume":"5","year":"2016","journal-title":"J Gastroenterol Hepatol Res"},{"key":"hep31595-bib-0053-20250824","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/obr.12436","article-title":"The effect of (L\u2010)carnitine on weight loss in adults: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"17","year":"2016","journal-title":"Obes Rev"},{"key":"hep31595-bib-0054-20250824","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/dc14-2852","article-title":"Improvement of nonalcoholic fatty liver disease with carnitine\u2010orotate complex in type 2 diabetes (CORONA): a randomized controlled trial","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"hep31595-bib-0055-20250824","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/ajg.2009.719","article-title":"L\u2010carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitisa randomized and controlled clinical trial","volume":"105","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"hep31595-bib-0056-20250824","first-page":"1","article-title":"The potential use of metabolic cofactors in treatment of NAFLD","volume":"11","year":"2019","journal-title":"Nutrients"},{"key":"hep31595-bib-0057-20250824","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003088-200342110-00002","article-title":"Pharmacokinetics of L\u2010carnitine","volume":"42","year":"2003","journal-title":"Clin Pharmacokinet"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31595","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:02:34Z","timestamp":1756080154000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31595","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"2020-04-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}